SILVER SPRING, MD. – With their increasing prevalence, drug shortages in the United States have led to delays in treatment, forced the use of less effective alternatives, and encouraged a burgeoning gray market that sells tough-to-obtain medications at highly inflated prices, according to stakeholders gathered at a recent Food and Drug Administration meeting.
Shortfalls in drug supply have increased in the United States, with 178 shortages of products reported in 2010, up from 61 in 2005, according to Dr. Edward Cox, coordinator of the FDA’s drug shortage program. Disproportionately affected are generic drugs and sterile injectable products; the latter accounted for two-thirds of the shortages last year. About half of the injectable shortages were caused by problems with product quality, followed by manufacturing delays (21%) and discontinuations (11%), and other issues including an increase in demand created by another shortage, he said at the meeting.
As with older generic drugs, there’s little financial incentive to produce older sterile injectables, which sell for as little as 48 cents for a 20-mL vial of propofol. In such cases, manufacturing glitches can often convince companies to pull the plug on a product, creating shortages.
Most hospitals aren’t immune. A June 2011 survey of 820 nonfederal, short-term, acute care hospitals by the American Hospital Association found that almost 99% had experienced one or more drugs shortages in the first 6 months of 2011; 44% reported at least 21 shortages during that time. In addition, nearly half reported experiencing drug shortages on a daily basis, 40% on a weekly basis, and 13% on a monthly basis.
Almost all these hospitals (96%) had experienced shortages of anesthesia for surgery, followed by drugs used for emergency care (91%), cardiovascular care (90%), GI/nutrition (89%), pain management (88%), infectious disease (83%), and oncology (66%).
Drug shortages have hit the fields of oncology and anesthesiology particularly hard, often causing the delay or postponement of clinical trials of cancer treatments.
Shortages of propofol and succinylcholine have been common. Dr. Frederick Blum, past president of the American College of Emergency Physicians, who practices in Morgantown, West Virginia, described being told there was no succinylcholine available when he recently requested it as he was about to intubate a trauma patient. When he asked for the next best drug, it wasn’t available either because supply had been depleted from the succinylcholine shortage. A third, less-than-ideal alternative was found. But Dr. Blum said that after 30 years of practice, during which time he probably has used succinylcholine thousands of times, he left that shift shaking his head about the need to resort to using a third-choice drug.
Before the shortage of succinylcholine was resolved earlier this year, shortages of the agent also resulted in postponed surgeries at Veterans Administration Medical Centers.
Generic Cancer Drugs Drying Up
Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, noted that many generic cancer drugs are in short supply. Such drugs, developed years ago, often are inexpensive and "remain mainstays of many currently available and effective cancer treatment programs," he said.
Drug Shortages Increasingly Take Toll on Care
Submitting your vote...
The Oncology Report
Comprehensive reports and expert commentary
on the latest advances in cancer treatment from
the world's major oncology meetings.